Pharmacokinetic properties of anti-influenza neuraminidase inhibitors (Q38084212)

28 August 2017

Pharmacokinetic properties of anti-influenza neuraminidase inhibitors (English)

1 reference

28 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

3

Nicholas J White

1 reference

28 August 2017

2

Joel Tarning

1 reference

28 August 2017

Kalayanee Chairat

1

1 reference

PubMed ID

23436258

28 August 2017

Niklas Lindegardh

series ordinal

4

1 reference

28 August 2017

24 January 2013

1 reference

The Journal of Clinical Pharmacology

28 August 2017

1 reference

28 August 2017

53

1 reference

28 August 2017

119-139

1 reference

28 August 2017

2

1 reference

28 August 2017

A history of influenza

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The pathology of influenza virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Anti-influenza drugs: the development of sialidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The biology of influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Developing new antiviral agents for influenza treatment: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Antimalarial combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Antiretroviral therapy in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Automated high-performance liquid chromatographic method for the determination of a neuraminidase inhibitor (GG167) in human serum by pre-column fluorescence derivatisation using benzoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Importance of collection tube during clinical studies of oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Development and validation of a high-throughput zwitterionic hydrophilic interaction liquid chromatography solid-phase extraction-liquid chromatography-tandem mass spectrometry method for determination of the anti-influenza drug peramivir in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Quantification of peramivir (a novel anti-influenza drug) in human plasma by hydrophilic interaction chromatography/tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Safety and pharmacokinetics of oseltamivir at standard and high dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics of high-dose oseltamivir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir (tamiflu) is a substrate of peptide transporter 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic a

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

What is the optimal therapy for patients with H5N1 influenza?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Anti-influenza virus activity of peramivir in mice with single intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Wartime tactic doubles power of scarce bird-flu drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Probenecid with oseltamivir for human influenza A (H5N1) virus infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir dosing for influenza infection in premature neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Developmental pharmacology--drug disposition, action, and therapy in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics of oseltamivir in young and very elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The metabolism and transplacental transfer of oseltamivir in the ex vivo human model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Drugs in pregnancy. Pharmacokinetics in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics of oseltamivir among pregnant and nonpregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics of oseltamivir in breast milk and maternal plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Peramivir for severe influenza infection in a patient with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The burden of obesity on infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Diet-induced obesity impairs the T cell memory response to influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Effect of obesity on the pharmacokinetics of drugs in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Parenteral peramivir treatment for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Combination chemotherapy for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Population pharmacokinetics of oseltamivir when coadministered with probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The low potential for drug interactions with zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270012440280

21 January 2018

Identifiers

DOI

10.1177/0091270012440280

1 reference

28 August 2017

1 reference

PubMed ID

23436258